Key Takeaway
Silymarin significantly reduced liver-related mortality in alcohol-related cirrhosis (10.0% vs 17.3%, p=0.01) and lowered AST in alcoholic liver disease, supporting its use as adjunctive therapy.
Summary
This systematic review with meta-analysis identified 65 papers on silymarin's clinical effects, of which 19 met inclusion criteria for double- or single-blind design. The review assessed silymarin across multiple liver conditions including toxic liver disease, viral hepatitis, and alcoholic liver cirrhosis.
For alcoholic liver disease, silymarin significantly reduced AST compared to placebo (p=0.01), though alkaline phosphatase showed no significant change. In liver cirrhosis patients (mostly alcohol-related), total mortality was 16.1% with silymarin vs. 20.5% with placebo (not statistically significant), but liver-related mortality was significantly lower at 10.0% vs. 17.3% (p=0.01).
The evidence for toxic liver diseases was described as scarce, and no beneficial effects were found for viral hepatitis, particularly hepatitis C. The authors concluded it is reasonable to employ silymarin as supportive therapy in Amanita phalloides poisoning and alcoholic liver cirrhosis (Child class A), while recommending further research for other applications.
Methods
Systematic review with meta-analysis. Searched for clinical trials on silymarin; 65 papers identified, 19 met inclusion criteria (double- or single-blind design). Evaluated outcomes across toxic liver disease, viral hepatitis, and alcoholic liver cirrhosis. Meta-analytic pooling performed for mortality and liver enzyme endpoints.
Key Results
- Alcoholic liver disease: AST significantly reduced with silymarin vs. placebo (p=0.01)
- Alkaline phosphatase: no significant difference
- Liver cirrhosis total mortality: 16.1% silymarin vs. 20.5% placebo (not significant)
- Liver-related mortality: 10.0% silymarin vs. 17.3% placebo (p=0.01)
- No benefit found for viral hepatitis (hepatitis C)
- Supports use in Amanita phalloides poisoning
Limitations
- Only 19 of 65 identified papers met quality criteria, indicating limited high-quality evidence
- Clinical evidence for toxic liver diseases described as scarce
- Most cirrhosis data from alcohol-related cases, limiting generalizability
- Studies varied considerably in design, dosing, and endpoints
- Published in 2008, so does not capture more recent NAFLD/NASH research